In some parts of the world, an orphan disease is a rare disease whose rarity means there is a lack of a market large enough to gain support and resources for discovering treatments for it, except by the government granting economically advantageous conditions to creating and selling such treatments. Orphan drugs are ones so created or sold.
- Incorporation of Rare Diseases into the Catalogues of Medical Insurance Reimbursement
- R&D and Marketing of Orphan Drugs
- Roles of Patient Groups in Orphan Drug R&D
- Conditional Approval of Marketing
- Patient Registration for Rare Diseases
- Significance and Value of Clinical Trial Exemption
- Therapeutic Developments
- Pre-Access Procedures
- Definition of Rare Diseases
- Testing of Pathogenic Genes
- Application of Genetic Testing
- Study of Rare Diseases by Telemedicine
- Patient Recruitment and Global Participation
- Promotion of Data Collection and Share
- Enterprise R&D Risk Management & Control
- Devising Plans for Orphan Drug R&D
- Pre-Clinical Studies of Safety and Efficacy
- Clinical Trials Targeting Rare Diseases
- Approved Drugs Turning to Orphan Drugs
The latest policies of rare diseases and orphan drugs will be interpreted.
Marketing environment and the latest trends will be analyzed.
New ideas of orphan drug R&D will be shared.
Researchers from Universities and Institutes, Patients
Personnels from Companies on Drug R&D
Clinicians
Dear Mr./Ms.
You have registered successfully, the registration information and attention has been sent to the contact and the participants of the mailbox, please note that check. If not received, please contact the general meeting
